Options Lab receives federal funding for COVID-19 prevention trial, ranking 2nd out of 438 in competition

As of June 25, 2020, the Options Lab received federal funding for a COVID-19 clinical trial which aims to investigate if a 14 day course of oral Kaletra (lopinavir/ritonavir), which is currently used as one strategy for HIV post-exposure prophylaxis (PEP), is effective as COVID-19 PEP. More information can be found here.

Read more